Did Aurobindo Destroy Its Credibility With FDA Along With A Microbial Plate?
This article was originally published in PharmAsia News
Executive Summary
A U.S. FDA warning letter coming on top of an import alert suggests the agency doesn't trust India-based Aurobindo Pharma's quality control
You may also be interested in...
Outsourcing Your Way Into Trouble: Pfizer Issues Recall After Indian Aurobindo Mislabels Bottles
India-based Aurobindo Pharma Ltd. may find itself in a little hot water with business partner Pfizer Inc. after forcing a recall because bottles of an anti-depressant drug may have been mislabeled as a benign prostatic hyperplasia treatment
GMP Warning Letter: Teva Preempts FDA In Disclosing Problems At Jerusalem Plant
Generic giant Teva took the unusual step of disclosing the entire contents of a Jan. 31 FDA warning letter about good manufacturing process failings, as part of a Securities and Exchange Commission filing it posted online two days later.
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).